The United Kingdom’s Healthtech and Medtech sectors are approaching a definitive inflection point as the market transitions into 2026. Following a period characterised by post-pandemic market corrections, valuation compression and capital scarcity between 2023 and 2025, the outlook for 2026 is one of strategic acceleration and structural evolution. This report predicts that 2026 will not merely represent a cyclical rebound but a fundamental shift in the operating logic of

The Mergers and Acquisitions (M&A) landscape for HealthTech and MedTech is poised for a significant strategic acceleration in 2026, transitioning from cautious, volume-driven dealmaking witnessed in previous years to high-value, transformative transactions. This resurgence is supported by stabilising credit markets, renewed corporate confidence, and a critical, anticipated pivot in US. antitrust enforcement policy, which is expected to facilitate large, strategic combinat

The field of vagus nerve neuromodulation (VNN) is undergoing a profound transformation, moving beyond its established applications to emerge as a cornerstone of bioelectronic medicine. While vagus nerve stimulation (VNS) has long been a recognised treatment for refractory epilepsy and treatment-resistant depression, recent technological breakthroughs and landmark clinical trial results are expanding its therapeutic reach into a wide array of chronic inflammatory, neurological

Closed-loop Vagus Nerve Stimulation (VNS) represents a profound evolution within bioelectronic medicine, transitioning from static, pre-programmed therapies to adaptive, personalised interventions.